Good Lifestyle

Millions have turned to medication in the past year losing weight , with four big names dominating space: Ozempic, Mounjaro, Wegovy and Zepbound. These drugs skyrocketed in popularity in the midst of "Ozempic obsession" in Hollywood, many celebrities admitting to take them to lose books quickly. But while manufacturers have largely silent on the non -essential use of their drugs, the manufacturer of Mounjaro is now expressed patients taking the medication for aesthetic weight loss.

In relation: The competitor Ozempique Mounjaro becomes even more popular - this is why .

Eli Lilly is the company behind the Mounjaro and Zepbounde Tirzepatid drugs. Mounjaro has been approved By the Food and Drug Administration of the United States (FDA) in 2022 as treatment for adults with type 2 diabetes 2 of last year, the The FDA approved Zepbound For chronic weight management in adults with obesity.

In a new advertising Released on February 23, the manufacturer of Mounjaro calls patients who take these drugs without meeting the FDA approval requirements. The announcement, entitled "Big Night", was published just before March 10 Oscars Awards, and offers photos of things you would see during a Hollywood award ceremony: sparkling gold dresses, red carpets , paparazzi and the curtain rising in a theater.

"Some people have used medicine never signified for them," said a voiceover. "For the smallest dress or the tuxedo. For a big night. For vanity. But that's not the point."

The announcement then goes to a scene with a woman dressed in ordinary clothes taking public transport.

"People whose health is affected by obesity is the reason why we are working on these drugs," continues the voiceover. "It doesn't matter who gets them."

Although advertising does not mention Mounjaro or Zepbound by its name, Eli Lilly CEO David Ricks said to cnn that it always works to transmit a message whose company is serious.

"We have a point of view on how these drugs are used," said Ricks. "These drugs have been invented for people with a serious health problem; they were not invented just to have someone who is a little better."

According to Latest data Centers for Disease Control and Prevention (CDC), obesity affects approximately 41.9% of adults in the United States.

"It's a disease," Ricks told CNN. "It is a metabolic disorder which, for most people, will not disappear without serious medical treatment ... so I do not think that we are going to make a lot of progress on this subject, which affects more than 100 million Americans, unless we deal with it is like a health problem, just as we do hypertension or arrhythmia or anything else. "

In relation: Big Ozempic Warning by Jillian Michaels: he makes you a "life prisoner".

The CEO said there were three specific reasons for which Eli Lilly reprimanded who has access to popular weight loss drugs: insurance coverage, shortages and type of research that was devoted to these drugs.

"We are far from being able to provide a billion people with these drugs with obesity, not to mention people who might want to lose weight cosmetically," Ricks told CNN. "So we have to prioritize, and this is what this announcement is to prioritize those who need it most."

The company has also not tested its drugs approved by the weight on patients who do not fall into one of the categories for which it is approved.

"We only studied it in an overweight or obesity population, and we have focused on people with chronic obesity complications," he said. "We cannot talk about the advantages and risks outside the population, so we think that it is responsible for pointing the light here, where the drug is most necessary."

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly. AE0FCC31AE342FD3A1346EBB1F342FCB